Toronto Stock Exchange Symbol: DND

    MISSISSAUGA, ON, Nov. 5 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND),
announced today that Larry Andrews, President and Chief Executive Officer of
the Company, will present a corporate update at Rodman & Renshaw's 10th Annual
Healthcare Conference, which is being held in New York City from November 10 -
12 at the New York Palace Hotel. Cipher's presentation will take place on
Wednesday, November 12, at 10:20am ET in the Holmes II Room. Larry Andrews
will be available for questions following his presentation.
    A live audio webcast of the presentation will be available through
www.cipherpharma.com.

    About Cipher Pharmaceuticals Inc.

    Cipher Pharmaceuticals is a drug development company focused on
commercializing novel formulations of successful, currently marketed molecules
using advanced drug delivery technologies. Cipher's strategy is to in-license
products that incorporate proven drug delivery technologies and advance them
through the clinical development and regulatory approval stages, after which
the products are out-licensed to international partners. Because Cipher's
products are based on proven technology platforms applied to currently
marketed drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. The Company's
lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and
Drug Administration and Health Canada in the first quarter of 2006. The
product is being marketed in the United States by Kowa Pharmaceuticals America
under the label Lipofen(R). In addition, Cipher is developing formulations of
the pain reliever tramadol (FDA approvable letter in May 2007) and the acne
treatment isotretinoin (FDA approvable letter in April 2007).

    Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and
has approximately 24 million shares outstanding. For more information, please
visit www.cipherpharma.com.